IN VITRO EVIDENCE

Retatrutide and Body Composition: What Trial Data Shows About Lean Mass and Gluteal Changes

Short answer: The retatrutide phase 2 trial (338 adults, NEJM 2023) reported mean weight loss of up to 24.2 percent at 48 weeks but did not publish regional body composition data, so the gluteal flattening that online communities call "RETA ass" cannot be read from the retatrutide dataset itself. Across GLP-1 receptor...

By Vitality Team6 min readUpdated 3 September 2026

Short answer: The retatrutide phase 2 trial (338 adults, NEJM 2023) reported mean weight loss of up to 24.2 percent at 48 weeks but did not publish regional body composition data, so the gluteal flattening that online communities call "RETA ass" cannot be read from the retatrutide dataset itself. Across GLP-1 receptor agonist trials, DEXA studies put lean mass at 25 to 40 percent of total weight lost, and exercise and protein intake studies show that ratio can be shifted. The pattern belongs to rapid, large weight loss as a class effect, not to one molecule.

Rapid, significant weight loss from GLP-1 receptor agonist research has drawn attention to a pattern that online communities have named "RETA ass": visible gluteal flattening associated with loss of both subcutaneous fat and lean tissue in the hip region. The term is colloquial, but the underlying body composition question is real and measurable.

What does the retatrutide phase 2 data show?

The phase 2 trial of retatrutide (Jastreboff et al., New England Journal of Medicine, 2023) enrolled 338 adults with obesity and reported mean body weight reductions of up to 24.2% at 48 weeks in the highest-exposure groups. These numbers are significant, exceeding the weight reductions observed in earlier GLP-1 receptor agonist trials of tirzepatide and semaglutide.

The trial focused on total body weight, BMI, and metabolic parameters. It did not publish granular, region-specific DEXA body composition data for the gluteal area. The body composition question, including fat-free mass changes, has been addressed in related GLP-1 agonist literature rather than in the retatrutide dataset specifically.

How much of the weight lost is lean mass?

Weight loss from any mechanism involves some proportion of lean tissue loss alongside fat reduction. In pharmacological weight loss research, the ratio of lean mass loss to total weight loss has consistently fallen between 25% and 40% in published DEXA studies across multiple GLP-1 receptor agonist trials.

A 2023 analysis of semaglutide 2.4 mg (the STEP trials, Wilding et al.) found that approximately 39% of total weight lost was lean mass. Tirzepatide data from SURMOUNT-1 reported a somewhat lower lean mass fraction, but the overall pattern holds: significant pharmacological weight reduction affects both fat and lean tissue.

Gluteal changes are particularly noticeable because the gluteal region carries both subcutaneous fat and significant muscle mass. Losing both simultaneously produces a visible contour change that is disproportionately apparent relative to total percentage of body weight lost.

What does concurrent exercise research show?

A growing body of evidence examines whether structured resistance training preserves lean mass during pharmacological weight loss. Key findings from the published literature:

A 2024 study (Lundgren et al., published in The Lancet Diabetes & Endocrinology) randomized liraglutide-assigned participants to supervised resistance training versus usual activity. The exercise group retained significantly more lean mass and showed improved functional capacity compared to controls, while total weight reduction was similar between groups.

These findings are consistent with the general exercise physiology literature: mechanical loading signals muscle protein synthesis pathways even when the body is in caloric deficit. The gluteal muscles (gluteus maximus, medius, and minimus) are among the largest muscle groups in the body and respond measurably to targeted resistance loading.

What does protein intake research show?

Adequate protein intake during weight loss is one of the most replicated findings in body composition research. Meta-analyses (Hector & Phillips, 2018; Wycherley et al., 2012) consistently show that higher protein intake during caloric deficit preserves more lean body mass compared to standard or low protein intakes.

In the context of GLP-1 receptor agonist-induced appetite suppression, total caloric intake often drops substantially. If protein intake drops proportionally, the lean mass preservation signal weakens. Several research groups have noted that tracking macronutrient composition during pharmacological weight loss is an underexplored variable that may explain variation in body composition outcomes between individuals and across studies.

What does this mean for body composition endpoints?

Total body weight reduction alone does not capture the compositional picture. DEXA or BIA measurements at regional sites, including gluteal and appendicular lean mass, provide more granular data on where tissue changes occur.
Concurrent variables such as physical activity level and dietary macronutrient composition are potential confounders that future study designs should control for, or at minimum record systematically.
The colloquial "RETA ass" phenomenon is, in research terms, a regional lean mass deficit compounded by subcutaneous fat loss. It is not unique to retatrutide. It appears across the GLP-1 receptor agonist class wherever weight loss is substantial and rapid.

Why is this research context and not a personal protocol?

The studies referenced above were conducted in regulated clinical settings with defined populations, standardized protocols, and ethics oversight. Their findings describe group-level observations.

Vitality Peps compounds are intended for laboratory research purposes only. They are not for human consumption. Nothing in this article constitutes personal advice, and no reader should interpret published trial data as a protocol for individual application.

Researchers interested in body composition endpoints during multi-receptor agonist studies should consult the primary literature referenced below and design their investigations under appropriate institutional oversight.

Frequently asked questions

Did the retatrutide trial measure gluteal or regional body composition?

No. The phase 2 trial reported total body weight, BMI and metabolic parameters. Regional DEXA data for the gluteal area was not published, so the body composition question is answered from related GLP-1 receptor agonist literature, not from the retatrutide dataset.

How much lean mass is lost with GLP-1 receptor agonist weight loss?

Published DEXA analyses across the class report lean mass at roughly 25 to 40 percent of total weight lost; the STEP 1 semaglutide analysis reported about 39 percent, and SURMOUNT-1 tirzepatide data a somewhat lower fraction. The exact share varies by trial, method and participant.

Is "RETA ass" specific to retatrutide?

No. In research terms it is a regional lean mass deficit compounded by subcutaneous fat loss, and it appears wherever weight loss is substantial and rapid across the GLP-1 receptor agonist class. Retatrutide draws attention because its trial weight loss figures are the largest published so far.

What study designs address the lean mass question?

Trials that add regional DEXA or BIA measurements, record physical activity and protein intake, and include structured exercise arms, such as the liraglutide plus exercise work published in 2024. Those variables are confounders that future retatrutide studies would need to control or record.

Is research-grade retatrutide the same as the product in the trial?

No. The trial evaluated a defined investigational product under clinical oversight. Research-grade retatrutide is a laboratory reagent supplied for research use only, with no clinical evidence of its own and no marketing authorisation anywhere.

References

Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340.
Lundgren JR, et al. Effect of liraglutide and exercise on body composition. Lancet Diabetes Endocrinol. 2024.
Hector AJ, Phillips SM. Protein recommendations for weight loss in elite athletes. Int J Sport Nutr Exerc Metab. 2018;28(2):170-177.
Wycherley TP, et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis. Am J Clin Nutr. 2012;96(6):1281-1298.